81068-26-0

Basic information

• Product Name: 3-(2-MORPHOLIN-4-YLETHOXY)BENZALDEHYDE
• Synonyms: 3-(2-MORPHOLIN-4-YLETHOXY)BENZALDEHYDE;CHEMBRDG-BB 7724803;3-(2-Morpholin-4-ylethoxy)benzaldehyde 97%;benzaldehyde, 3-[2-(4-morpholinyl)ethoxy]-;3-[2-(4-morpholinyl)ethoxy]benzaldehyde(SALTDATA: HCl);4-[2-(3-Formylphenoxy)ethyl]morpholine;3-(2-morpholinoethoxy)benzaldehyde;3-[2-(Morpholin-4-yl)ethoxy]benzaldehydehydrochloride
• CAS NO: 81068-26-0
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Mol File: 81068-26-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 391.6 °C at 760 mmHg
• Flash Point: 190.6 °C
• Appearance: /
• Density: 1.141 g/cm³
• Vapor Pressure: 2.43E-06mmHg at 25°C
• Refractive Index: 1.552
• CAS DataBase Reference: 3-(2-MORPHOLIN-4-YLETHOXY)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-MORPHOLIN-4-YLETHOXY)BENZALDEHYDE(81068-26-0)
• EPA Substance Registry System: 3-(2-MORPHOLIN-4-YLETHOXY)BENZALDEHYDE(81068-26-0)

Safety Data

• Hazard Codes: C
• HazardClass: IRRITANT
• Hazardous Substances Data: 81068-26-0(Hazardous Substances Data)

Usage

General Description

3-(2-Morpholin-4-ylethoxy)benzaldehyde is a chemical compound with the molecular formula C14H17NO3. It is an aromatic aldehyde with a morpholine functional group and an ether linkage. 3-(2-MORPHOLIN-4-YLETHOXY)BENZALDEHYDE is used in organic synthesis and pharmaceutical research, and it has potential applications in the development of new drugs and pharmaceuticals. Additionally, it may be used as an intermediate in the production of other chemical substances. The presence of the morpholine and benzaldehyde moieties in this compound makes it a versatile building block for the creation of a wide range of complex organic molecules.

InChI:InChI=1/C13H17NO3/c15-11-12-2-1-3-13(10-12)17-9-6-14-4-7-16-8-5-14/h1-3,10-11H,4-9H2

Upstream product

• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 100-83-4 meta-hydroxybenzaldehyde 
• 110-91-8 morpholine 
• 186191-19-5 m-(2-bromoethyloxy)benzaldehyde 
• 3240-94-6 N-(2-chlorethyl)morpholine 

Downstream Products

• 1172118-34-1 2-{3-[2-(morpholino)ethoxy]phenyl}-4,5-diphenylimidazole 
• 1155224-41-1 6-amino-5-[{3-(2-morpholin-4-ylethoxy)benzylidene}amino]-1,3-dimethyluracil 
• 942950-86-9 2-(4-(6-Chloro-2-(3-(2-morpholinoethoxy)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide 
• 1241507-30-1 N-(5-iodo-pyridin-2-yl)-N'-[1-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-meth-(E)-ylidene]-hydrazine 
• 1443252-44-5 N-(5-fluoropyridin-2-yl)-N'-[1-[3-(2-morpholin-4-ylethoxy)phenyl]methylidene]hydrazine 
• 1443252-45-6 6-fluoro-3-[3-(2-morpholin-4-ylethoxy)phenyl][1,2,4]triazolo[4,3-a]pyridine 
• 1616110-98-5 (Z)-2-[3-(2-morpholin-4-ylethoxy)-benzylidene]-3-oxo-2,3-dihydrobenzofuran-7-carboxamide 

Relevant articles and documents

Bronchospasmolytic activity and adenosine receptor binding of some newer 1,3-dipropyl-8-phenyl substituted xanthine derivatives

The aldehyde derivatives of 1,3-dipropyl xanthines as described in this paper, constitutes a new series of selective adenosine ligands displaying bronchospasmolytic activity. The effect of substitution at third- and fourth-position of 8-phenyl xanthine ha

Discovery and structure-activity relationship of novel 2,3- dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2 h)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 Inhibitors

Novel substituted 2,3-dihydrobenzofuran-7-carboxamide (DHBF-7-carboxamide) and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide (DHBF-3-one-7-carboxamide) derivatives were synthesized and evaluated as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). A structure-based design strategy resulted in lead compound 3 (DHBF-7-carboxamide; IC50 = 9.45 μM). To facilitate synthetically feasible derivatives, an alternative core was designed, DHBF-3-one-7-carboxamide (36, IC50 = 16.2 μM). The electrophilic 2-position of this scaffold was accessible for extended modifications. Substituted benzylidene derivatives at the 2-position were found to be the most potent, with 3′,4′-dihydroxybenzylidene 58 (IC50 = 0.531 μM) showing a 30-fold improvement in potency. Various heterocycles attached at the 4′-hydroxyl/4′-amino of the benzylidene moiety resulted in significant improvement in inhibition of PARP-1 activity (e.g., compounds 66-68, 70, 72, and 73; IC50 values from 0.718 to 0.079 μM). Compound 66 showed selective cytotoxicity in BRCA2-deficient DT40 cells. Crystal structures of three inhibitors (compounds (-)-13c, 59, and 65) bound to a multidomain PARP-1 structure were obtained, providing insights into further development of these inhibitors.

Synthesis of a series of 8-(substituted-phenyl)xanthines and a study on the effects of substitution pattern of phenyl substituents on affinity for adenosine A1 and A2A receptors

A new series of 8-(substituted-phenyl)xanthines have been synthesized and compounds were evaluated for their affinity for A1 and A2 adenosine receptors (AR) using radioligand binding assays. The effects of varying the positions of 8-phenyl substituents on affinity and selectivity at A1 and A2A adenosine receptors have been studied. Isovanilloid 1,3-dimethyl-8-[4-methoxy-3-(2-morpholin-4-ylethoxy)phenylxanthine (9d) displayed the highest affinity and selectivity towards A2A AR subtypes with Ki = 100 nM over A1 receptors (Ki > 100 mM). It has been observed that substitution pattern on 8-phenyl group greatly affects the affinity and selectivity at adenosine receptors, with A2A tolerating bulkier substituents than did A1 receptors.